Prevail Therapeutics Inc. (NASDAQ:PRVL) has been given a consensus broker rating score of 1.13 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.

Brokers have set a one year consensus target price of $20.00 for the company and are anticipating that the company will post ($0.56) EPS for the current quarter, according to Zacks. Zacks has also assigned Prevail Therapeutics an industry rank of 87 out of 256 based on the ratings given to related companies.

Several research analysts recently commented on PRVL shares. Morgan Stanley set a $70.00 target price on Edison International and gave the stock a “hold” rating in a research report on Monday, July 15th. Wedbush set a $19.00 target price on Symantec and gave the stock a “hold” rating in a research report on Monday, July 15th. Cowen reaffirmed a “buy” rating on shares of Avrobio in a research report on Monday, July 15th. Finally, Bank of America set a $68.00 price objective on Inphi and gave the company a “buy” rating in a report on Monday, July 15th.

In related news, Director Carl L. Gordon acquired 882,352 shares of the business’s stock in a transaction on Monday, June 24th. The stock was bought at an average cost of $17.00 per share, with a total value of $14,999,984.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of PRVL stock opened at $11.64 on Tuesday. Prevail Therapeutics has a one year low of $9.83 and a one year high of $16.90.

Prevail Therapeutics Company Profile

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Featured Story: Trading Strategy

Get a free copy of the Zacks research report on Prevail Therapeutics (PRVL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with's FREE daily email newsletter.